rxstat › Drug prices › Pazopanib

Pazopanib price in Canada

No current shortage

Source: Health Canada shortage reports · Updated Jul 9, 2026

Pazopanib 200 mg tablet costs about $18.21 to $30.97 per tablet on public drug plan price lists across 6 provinces, before the pharmacy's dispensing fee.

Pazopanib has no current shortage reported in Canada. It has been in shortage before; the history is below.

Price by province

Strength and formABMBONNBNSPENL
200 mg Tabletper tablet$30.97not covered$18.21$30.97$18.21$18.21$18.21$19.85
Plan coverageNot coveredPrice listCoveredSpecial approvalSpecial approvalPrice listPrice list

Lowest price per unit among each province's covered products, with the brand price where it is notably higher. A dash means the province does not list it.

Detailed price and coverage in your province:

What you'll pay at the pharmacy

These are the prices public drug plans list for the drug itself. At the counter, pharmacies add a dispensing fee and in some provinces a markup, so paying cash costs more, and for cheap generics the fee is often more than the drug. If you have a public or private plan, your share depends on its deductible and co-pay. In Ontario, the plan pays only up to the lowest interchangeable price ($30.97 per tablet for 200 mg).

Listed products by province

Alberta: 3 products
  • Pms-Pazopanib 200 mg Tablet · PMS
    DIN 02525666 · $30.97/tablet · Not covered
  • Auro-Pazopanib 200 mg Tablet · EUG
    DIN 02552957 · $30.97/tablet · Not covered
  • Votrient 200 mg Tablet · NOV
    DIN 02352303 · $40.95/tablet · Not covered
Manitoba: 3 products
  • Auro-Pazopanib 200 mg Tablet · EUG
    DIN 02552957 · $18.21/tablet · Price list
  • Pms-Pazopanib 200 mg Tablet · PMS
    DIN 02525666 · $18.21/tablet · Price list
  • Votrient 200 mg Tablet · NVT
    DIN 02352303 · $40.22/tablet · Price list
Ontario: 3 products
  • Pms-Pazopanib 200 mg Tablet · Pharmascience Inc.
    DIN 02525666 · $30.97/tablet · Covered
  • Auro-Pazopanib 200 mg Tablet · Eugia Pharma Inc.
    DIN 02552957 · $30.97/tablet · Covered
  • Votrient 200 mg Tablet · GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care
    DIN 02352303 · $42.14/tablet · Covered
New Brunswick: 3 products
  • Votrient 200 mg Tablet · NVR
    DIN 02352303 · $18.21/tablet · Special approval
  • Pms-Pazopanib 200 mg Tablet · PMS
    DIN 02525666 · $18.21/tablet · Special approval
  • Auro-Pazopanib 200 mg Tablet · ARO
    DIN 02552957 · $18.21/tablet · Special approval
Nova Scotia: 3 products
  • Votrient 200 mg Tablet · NVR
    DIN 02352303 · $18.21/tablet · Special approval
  • Pms-Pazopanib 200 mg Tablet · PMS
    DIN 02525666 · $18.21/tablet · Special approval
  • Auro-Pazopanib 200 mg Tablet · EUG
    DIN 02552957 · $18.21/tablet · Special approval
Prince Edward Island: 3 products
  • Votrient 200 mg Tablet · NVR
    DIN 02352303 · $18.21/tablet · Price list
  • Pms-Pazopanib 200 mg Tablet · PMS
    DIN 02525666 · $18.21/tablet · Price list
  • Auro-Pazopanib 200 mg Tablet · ARO
    DIN 02552957 · $18.21/tablet · Price list
Newfoundland and Labrador: 3 products
  • Auro-Pazopanib 200 mg Tablet · EUG
    DIN 02552957 · $19.85/tablet · Price list
  • Pms-Pazopanib 200 mg Tablet · PMS
    DIN 02525666 · $19.85/tablet · Price list
  • Votrient 200 mg Tablet · NVR
    DIN 02352303 · $45.59/tablet · Price list

Price sources: Ontario Drug Benefit Formulary (Oct 30, 2026) · Alberta Drug Benefit List and Alberta Blue Cross price list (Nov 1, 2026) · New Brunswick Drug Plans Formulary (Nov 1, 2026) · Nova Scotia Pharmacare Formulary (Nov 1, 2026) · PEI Pharmacare Maximum Reimbursable Price List (Nov 24, 2026) · Newfoundland and Labrador Interchangeable Drug Products Formulary (Oct 1, 2026) · Manitoba Drug Interchangeability Formulary (Nov 1, 2026). Other provinces and territories will be added as their public price lists are brought in.

Shortage status

Products affected
0 / 1
Reports on file
2

Shortage history

2024 2025 2026

Shortage history (red bands = periods in shortage).

Reports by product

The DIN is printed on your prescription label.

Resolved
PMS-PAZOPANIB
200MG · TABLET · PHARMASCIENCE INC
DIN 02525666 · ended Oct 14, 2023 · Disruption of the manufacture of the drug.
Resolved
PMS-PAZOPANIB
200MG · TABLET · PHARMASCIENCE INC
DIN 02525666 · ended Oct 13, 2023 · Disruption of the manufacture of the drug.

What's happening

There are no active shortage reports for Pazopanib. Health Canada has 2 historical reports on file for this drug, so supply has been disrupted before; the change log below shows the history.

Recent changes

Common questions

How much does Pazopanib cost in Canada?

Pazopanib 200 mg tablet costs about $18.21 to $30.97 per tablet on public drug plan price lists across 6 provinces, before the pharmacy's dispensing fee.

Is Pazopanib covered by provincial drug plans?

On the public plans' own lists: Alberta: not covered; Manitoba: price list; Ontario: covered; New Brunswick: special approval; Nova Scotia: special approval; Prince Edward Island: price list; Newfoundland and Labrador: price list. "Special approval" means the plan covers it only for some patients, on a request from the prescriber. "Price list" means the province publishes its price but not its coverage.

When will Pazopanib be back in stock in Canada?

Pazopanib has no active shortage; supply is normal per Health Canada reports.

Why is Pazopanib in shortage?

It isn't currently. Past reports and their reasons are listed above.

What can my pharmacist do about it?

Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.

Email alerts

Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.

Related drugs

Guides: what to do when your medication is in shortage · how to read shortage reports

Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.